Details for Patent: 8,835,430
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,835,430 protect, and when does it expire?
Patent 8,835,430 protects ZYKADIA and is included in two NDAs.
This patent has one hundred and one patent family members in thirty-one countries.
Summary for Patent: 8,835,430
| Title: | 2,4-pyrimidinediamine compounds and their uses |
| Abstract: | The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. |
| Inventor(s): | Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (San Francisco, CA), Holland; Sacha (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander (Reedsport, OR) |
| Assignee: | Rigel Pharmaceuticals, Inc. (South San Francisco, CA) |
| Application Number: | 14/038,521 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,835,430
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
| Novartis | ZYKADIA | ceritinib | TABLET;ORAL | 211225-001 | Mar 18, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,835,430
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 451104 | See Plans and Pricing | |||
| Austria | 524184 | See Plans and Pricing | |||
| Australia | 2003208931 | See Plans and Pricing | |||
| Australia | 2003265336 | See Plans and Pricing | |||
| Australia | 2008252053 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
